Cargando…
The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage,...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972400/ https://www.ncbi.nlm.nih.gov/pubmed/2039707 |
_version_ | 1782135020176015360 |
---|---|
author | Gion, M. Mione, R. Nascimben, O. Valsecchi, M. Gatti, C. Leon, A. Bruscagnin, G. |
author_facet | Gion, M. Mione, R. Nascimben, O. Valsecchi, M. Gatti, C. Leon, A. Bruscagnin, G. |
author_sort | Gion, M. |
collection | PubMed |
description | CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours). |
format | Text |
id | pubmed-1972400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1991 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19724002009-09-10 The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Gion, M. Mione, R. Nascimben, O. Valsecchi, M. Gatti, C. Leon, A. Bruscagnin, G. Br J Cancer Research Article CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours). Nature Publishing Group 1991-05 /pmc/articles/PMC1972400/ /pubmed/2039707 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Gion, M. Mione, R. Nascimben, O. Valsecchi, M. Gatti, C. Leon, A. Bruscagnin, G. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. |
title | The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. |
title_full | The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. |
title_fullStr | The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. |
title_full_unstemmed | The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. |
title_short | The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. |
title_sort | tumour associated antigen ca15.3 in primary breast cancer. evaluation of 667 cases. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972400/ https://www.ncbi.nlm.nih.gov/pubmed/2039707 |
work_keys_str_mv | AT gionm thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT mioner thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT nascimbeno thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT valsecchim thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT gattic thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT leona thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT bruscagning thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT gionm tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT mioner tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT nascimbeno tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT valsecchim tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT gattic tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT leona tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases AT bruscagning tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases |